Suspected Counterfeit M-30 Oxycodone Pill Exposures and Acute Withdrawals Reported from a Single Hospital — Toxicology Investigators Consortium Core Registry, U.S. Census Bureau Western Region, 2017–2022
MMWR. Morbidity and Mortality Weekly Report · 2024
DOI: 10.15585/mmwr.mm7329a2 ↗Kurz gefasst
Fachartikel in der Zeitschrift MMWR. Morbidity and Mortality Weekly Report, 2024. Verfasst von Emily Glidden und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Oxycodone, Registries, Counterfeit Drugs. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Availability of counterfeit prescription pills (counterfeit pills) containing illegally made fentanyl, including counterfeit M-30 oxycodone (counterfeit M-30) pills, has risen sharply in the United States and has been increasingly linked to overdose deaths. In 2023, approximately 115 million counterfeit pills were seized in U.S. High Intensity Drug Trafficking Areas. However, clinical data on counterfeit pill-related overdoses are limited. Medical toxicology consultations during 2017-2022 from one U.S. Census Bureau Western Region hospital participating in the Toxicology Investigators Consortium Core Registry were analyzed. A total of 352 cases suspected to involve counterfeit M-30 pills, including 143 (40.6%) cases of fentanyl exposure and 209 (59.4%) cases of acute withdrawal were identified; consultations increased from three in 2017, to 209 in 2022. Patients aged 15-34 years accounted for 95 (67.4%) exposure cases. Among all patients with exposures, 81.1% were hospitalized, 69.0% of whom were admitted to an intensive care unit. Additional substances were detected in 131 (91.6%) exposures. Providing outreach to younger persons misusing prescription pills, improving access to and distribution of harm reduction tools including fentanyl test strips and naloxone, and promoting linkage of persons treated for overdose in hospitals to harm reduction and substance use treatment services are strategies to reduce morbidity associated with use of counterfeit M-30.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Glidden, E., Gladden, R. M., Dion, C., Spyres, M. B., Seth, P., Aldy, K., Mustaquim, D., & Toxicology Investigators Consortium (ToxIC) (2024). Suspected Counterfeit M-30 Oxycodone Pill Exposures and Acute Withdrawals Reported from a Single Hospital — Toxicology Investigators Consortium Core Registry, U.S. Census Bureau Western Region, 2017–2022. MMWR. Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm7329a2
Vancouver
Glidden E, Gladden RM, Dion C, Spyres MB, Seth P, Aldy K, et al. Suspected Counterfeit M-30 Oxycodone Pill Exposures and Acute Withdrawals Reported from a Single Hospital — Toxicology Investigators Consortium Core Registry, U.S. Census Bureau Western Region, 2017–2022. MMWR. Morbidity and Mortality Weekly Report. 2024. doi:10.15585/mmwr.mm7329a2
BibTeX
@article{Glidden2024,
author = {Glidden, Emily and Gladden, R Matthew and Dion, Chris and Spyres, Meghan B and Seth, Puja and Aldy, Kim and Mustaquim, Desiree and Toxicology Investigators Consortium (ToxIC), Toxicology Investigators Consortium (ToxIC)},
title = {Suspected Counterfeit M-30 Oxycodone Pill Exposures and Acute Withdrawals Reported from a Single Hospital — Toxicology Investigators Consortium Core Registry, U.S. Census Bureau Western Region, 2017–2022},
journal = {MMWR. Morbidity and Mortality Weekly Report},
year = {2024},
doi = {10.15585/mmwr.mm7329a2}
}
EUVIMED